HIV / AIDS in the News

New data adds to case for bictegravir and lenacapavir in HIV - The Pharma Letter

 

[CROI 2026] [Press release] Merck announces late-breaking data from three Phase 3 trials evaluating doravirine/islatravir, an investigational, once-daily, two-drug regimen for the treatment of adults living with HIV-1 - European AIDS Treatment Group

 

Thousands of Floridians could lose HIV medication - JaxToday

 

From Ending the HIV Epidemic to Uncertain Ground: PrEP4All's Peter Staley - AJMC

 

Counting the costs of global HIV funding disruptions - Aidsmap

 

BIC LEN HIV treatment experienced comorbidites - Infectious Disease Special Edition

 

HIV medications could be cut off as of Sunday for thousands of Floridians - WGCU

 

HIV drug medication bill moving through GA legislature - 11Alive.com

 

[CROI 2026] aidsmap: Dual immune modulators delay, but don’t prevent, HIV rebound after stopping antiretrovirals - European AIDS Treatment Group

 

Military+HIV+enlistment+ban+upheld+by+4th+circuit - North Carolina Lawyers Weekly

 

[CROI 2026] aidsmap: Oropharyngeal cancer is becoming more common in heterosexual men with HIV - European AIDS Treatment Group

 

Analysis of 9vHPV Vaccination Benefits in Men With HIV - Docwire News

 

Bictegravir/Lenacapavir Combo Pill Could Replace Complex HIV Treatment - poz.com

 

Oral Cancer Is Rising Among People With HIV - poz.com

 

CNBC Changemakers and Power Players Podcast: Gilead Sciences Chief Commercial & Corporate Affairs Officer and 2026 CNBC Changemaker Johanna Mercier on ending HIV epidemic, life hacks, and her leadership superpower - CNBC

 

Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data - BioSpace

 

In a city with high HIV rates, one free clinic struggles to survive - WHRO

 

CROI 2026 highlights depression and cognitive vulnerability in HIV - bioworld.com

 

Kenya rolls out twice-yearly HIV prevention shot in Nairobi slum - africanews.com

 

PECO profits soar; HIV resources in one spot; Funeral cost assistance | Morning Roundup - Billy Penn at WHYY

 

Kenya becomes first in East Africa to launch six-month HIV prevention injection - WHO | Regional Office for Africa

 

South Africa: A year after USAID cuts - Al Jazeera

 

ViiV’s four-monthly HIV drug maintains viral suppression at 12 months - Clinical Trials Arena

 

Gilead data show investigational HIV combination maintains viral suppression - PharmaTimes

 

The 2026 Ruby Gala Makes Intersectional HIV Treatment Possible - Nfocus

 

HIV Stigma is Pervasive and Increasing Among US Adults - Williams Institute

 

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment - fda.gov

 

Breaking barriers: advancing health equity for persons with disabilities in HIV care and treatment - World Health Organization (WHO)

 

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy - BioSpace

 

New documentary ‘Ending HIV: The Journey to a Vaccine’ premieres at Boston’s Museum of Science - The Tufts Daily